The unexpected global epidemic of COVID-19 epidemic gave birth to the scene revolution in the field of medical testing, and the home testing track completed a historic leap in 2021 and officially entered the first year of industrialization. After three years of policy iteration, technology precipitation and market verification, this field has formed a three-dimensional driving pattern of "policy perfection+core technology breakthrough+consumer cognition maturity". With the commercialization of innovative technology, the home testing market is entering the eve of the outbreak, and a new wave of medical and health industry has arrived.
01, 100 billion track global market fiery policy Dongfeng detonated high-growth market
The COVID-19 epidemic has changed the attitude of European and American national regulators to home self-inspection. According to the statistics of relevant securities institutions, the population of countries that have opened home inspection is close to 800 million. According to the report of Arterial Network, overseas home inspection products of companies such as Everlywell and LetsGetChecked have landed on platforms such as pharmacies and e-commerce.
Previously, domestic policies had strict control over home testing, and products were emerging in an endless stream under the hot demand. Until the end of 2020, National Medical Products Administration issued the "Guiding Principles for the Registration Technology Review of Home in vitro Diagnostic Medical Devices", and the attention of home testing rose rapidly. A large number of enterprises began to lay out related businesses, and this blue ocean market gradually developed to standardization.
According to relevant data institutions, the global home health testing platform market sales reached $3.306 billion in 2021, and it is estimated that by 2028, the global home health testing platform market will increase to $11.273 billion, with a compound annual growth rate of 19.04%.
According to the calculation of relevant research institutions, the market of household medical devices in China has increased from 53.33 billion yuan in 2017 to 102.53 billion yuan in 2021, and will reach 178.36 billion yuan in 2026, with a compound growth rate of 11.14% from 2021 to 2026. The "2021 White Paper on the Trend of Internet Household Health Devices in China" also shows that the monitoring scene of various diseases has gradually changed from hospital physical examination to daily home self-inspection.
According to "Blue Book of China Medical Device Industry (2024)", the market size of in vitro diagnosis (IVD) in China has increased from 43 billion yuan in 2016 to 118.5 billion yuan in 2023, with a compound annual growth rate of 15.58%. It is estimated that the market size of in vitro diagnosis in China will exceed 190 billion yuan in 2029, with a compound annual growth rate of 8.2% compared with 2023.
"Healthy China 2030" Planning Outline points out that "treating diseases as the center" should be changed to "promoting health as the center". China is entering the era of national health, and home testing will become one of the important health testing scenarios.
In the national health protection system, 1.02 million primary medical institutions and more than 30,000 grade hospitals in China have jointly built a "pyramid" medical service network. Compared with grade hospitals, primary medical institutions are faced with double dilemmas: first, there is a significant gap in hardware configuration; Second, the structural imbalance of professional talents. This superposition effect of "equipment shortage" and "talent shortage" has led to a long-term high rate of referral from counties across the country, highlighting the deep contradiction between the ability of primary diagnosis and treatment and the health needs of residents. With the comprehensive promotion of graded diagnosis and treatment system, improving the detection and diagnosis ability of primary medical institutions has become a key breakthrough to solve the dilemma of "difficult and expensive medical treatment".
It is not difficult to see that family and primary medical institutions will become the two core markets of home testing products.
Huaan Securities' Report on the Trend of Medical Scene Reconstruction reveals that the outpatient service scene in China is undergoing a structural shift-42.7% of the daily average outpatient volume in tertiary hospitals has the feasibility of transferring to grassroots and family scenes. The new technology of POCT, represented by microfluidic chip and quantum dot detection platform, is breaking through the application barriers of family scenes: when these instant detection data are directly connected to regional medical centers through the 5G Internet of Things, it can effectively help tertiary hospitals to realize outpatient diversion, which is in strategic response to the goal of 25% primary first-visit rate set in the "Comprehensive Capacity Improvement Plan of County Hospitals in Thousand County Project". The report predicts that by 2026, every 1 percentage point increase in the penetration rate of home POCT equipment will release about 3.7 billion yuan of market incremental space.
02, one-stop home health management, the king of the market with a high growth rate of 100 billion yuan!
The market with a high growth rate of 100 billion yuan is ready to go. What kind of enterprises and products can stand out?
In an article, Arterial Network pointed out that, unlike the conventional diagnosis in medical institutions, home-based diagnosis has a higher demand for convenience, minimally invasive, painless and accurate.
"Accuracy", the home test results need to be medical-grade accuracy, which is the lifeline of home test products; "Trace", home testing users have higher requirements for sampling convenience and experience, and need to achieve minimally invasive, painless and trace sample collection; "Micro-project", because micro-samples can't detect hundreds of projects like professional medical institutions, it is necessary to accurately select appropriate projects that can accurately reflect human health.
Cebolan learned that the domestic market will usher in the first real home testing product, which also indicates that a new era is about to open.
This product comes from Chongqing Juce Life Health Technology Co., Ltd. (hereinafter referred to as Juce), a one-stop home health testing solution provider.
Juce is an innovative medical science and technology enterprise introduced by Chongqing Liangjiang New District. It employs domestic senior R&D personnel and engineers, focusing on the research and development, production and service of home health testing products, and is committed to realizing the family, automation, accuracy and cloud of diagnostic products.
Like many start-ups, Juce forges its core competitiveness through independent research and development, and drives industrial development with innovative products. At present, there are three platforms for in vitro diagnosis and detection: quantum dots, dry chemistry+electrochemistry and colloidal gold. The products cover many key fields such as respiratory tract infection, digestive tract, cardiovascular system, endocrine, acute and chronic disease monitoring.
Different from the existing testing products in the market, Home Testing innovatively put forward a complete set of closed-loop solutions from "sampling-testing-diagnosis and treatment" to meet the needs of users for one-stop home health management, which fully meets the requirements of convenience, minimally invasive, painless and accurate home testing products.
03, independent research and development, innovative technology to help health prevention and treatment of chronic diseases in China.
In the sampling link, sampling is carried out through a disposable sterile peripheral blood collection system. The blood sampler adopts an innovative plunger-type negative pressure adsorption propulsion system, which can complete independent sampling in two minutes without professionals, with high convenience. Compared with the traditional vein and fingertip blood collection, the blood collection site is in the deltoid muscle of the upper arm, and the sensitivity is low, thus truly realizing a slightly painless blood collection experience. Say goodbye to the fear of blood collection by hiding microneedles. It can be used for blood collection in laboratory departments, outpatient departments, emergency departments and other departments of grade hospitals and primary medical institutions, and is more convenient for home patients to collect blood by themselves.
The detection link is completed by a multifunctional detector and a quantum dot fluorescence immunochromatography analyzer independently developed by Habitat Test. One sampling can realize multi-item joint detection, which not only plays an important role in hospitals and clinics, but also is designed to be suitable for home detection.
The multifunctional detector can be used to detect common diseases, cooperate with the daily monitoring of patients with chronic diseases, and manage chronic diseases. It can also be used for regular inspection of "not sick" people, timely finding asymptomatic diseases, early intervention and long-term scientific management.
The quantum dot fluorescence immunochromatography analyzer for residential measurement adopts the international leading quantum dot and immunochromatography technology, which has the characteristics of high sensitivity, high specificity and good stability, and ensures the accuracy of the detection results. It can be used for early screening and auxiliary diagnosis of diseases. It has a wide range of detection items and high expansibility, and also plays a huge role in disease monitoring and health management.
In the field of home testing, the convenience of testing is only the basic requirement, and the real core competitiveness lies in the closed loop of professional report interpretation and follow-up health management services. By integrating three core modules, the residential smart medical cloud platform builds a whole-process health service system: firstly, relying on DeepSeek to realize intelligent interpretation and multi-dimensional analysis of test reports, and simultaneously establish dynamically updated family health records; Secondly, docking the Internet hospital system to realize the seamless connection from report interpretation to online expert consultation; Form a complete service chain. Provide users with an integrated health solution covering the whole life cycle and covering home scenes.
The wave of aging is sweeping, and the health crisis is imminent.
According to the National Bureau of Statistics, by 2023, the population aged 60 and over in China reached 297 million, accounting for 21.1% of the total population, and there was one silver-haired person in every five people; The population aged 65 and over is 217 million, accounting for 15.4%. This means that one out of every four elderly people in the world is Chinese, and China has entered a moderately aging society. More seriously, over 75% of the elderly suffer from at least one chronic disease, and the demand for health management is on the rise.
Looking back at the data, as early as 2012, the National Health and Family Planning Commission sounded the alarm: the deaths caused by chronic diseases accounted for 86.6% of the total deaths in China, and the disease burden accounted for about 70% of the total disease burden. In 2021, cardiovascular diseases, tumors and chronic respiratory diseases ranked among the top three in mortality, and chronic diseases suddenly became the number one threat to national health.
Policy escort, anchoring the goal of healthy China
The State Council, the Central Committee of the Communist Party of China issued the Outline of Healthy China 2030: By 2030, the premature mortality rate of major chronic diseases will be reduced by 30% compared with 2015. To achieve this goal, a more efficient and inclusive health management model is urgently needed.
Home testing is broken, and home testing leads the industry to change.
In this era, home detection has become the key to solve the problem. Home measurement products stand out with three core advantages:
1、For consumers: Say goodbye to the tedious queue of hospital registration, and complete the family health examination without leaving home.
2、For primary medical institutions: carry out inspection at low cost, present the test results accurately and quickly, greatly improve the diagnosis and treatment ability, and realize the cost-effective medical upgrade.
3、Different from a single product on the market, Juce builds an ecology of "product+closed-loop service" and a whole life-cycle health management chain of "detection+health management" to provide users with one-stop health solutions.
The popularity of 100 billion home testing has emerged, and the demeanor of the king of home testing has begun to appear. The future commercial performance is worth looking forward to.
Disclaimer: This article is only for the purpose of knowledge exchange and sharing and popular science, and does not involve commercial propaganda, and is not used as relevant medical guidance or medication advice. If the article is infringing, please contact to delete it.
Our product recommendation:
1.111243-34-6 https://www.bicbiotech.com/product_detail.php?id=6347
2.1132-17-8 https://www.bicbiotech.com/product_detail.php?id=6348
3.58076-33-8 https://www.bicbiotech.com/product_detail.php?id=6349
4.21095-40-9 https://www.bicbiotech.com/product_detail.php?id=6350
5.1256345-66-0 https://www.bicbiotech.com/product_detail.php?id=6303
